Does chlorthalidone stepped-care therapy improve life expectancy in patients with isolated systolic hypertension?
Short-term treatment (4.5 years) of isolated systolic hypertension with chlorthalidone is associated with a long-term survival benefit at 22 years.
In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepped-care therapy for 4.5 years was associated with longer life expectancy at 22 years of follow-up.
Kostis et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: